Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
3 pending office actions • 2 art units • 2 examiners • 0 of 3 (0%) have an AI response strategy ready
Oragenics Inc. has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed across 2 examiners and 2 art units, creating some separation in examination context.
BAKSHI, PANCHAM is the busiest examiner, with 2 pending actions. The two matters before that examiner may benefit from aligned biotechnology claim strategy and disclosure review, while the other matter should be assessed against its separate examination record.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (67%) |
| §103 only | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BAKSHI, PANCHAM | 2 | 76.7% | +30.2% |
| HALL, DEANNA K | 1 | 75.7% | +15.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18702776 | BREATH-POWERED NASAL DEVICES FOR TREATMENT OF TRAUMATIC BRAIN INJURY (TBI), INCLUDING CONCUSSION, AND METHODS | HALL, DEANNA K | 215d overdue |
| 18653138 | C-20 STEROID COMPOUNDS, COMPOSITIONS AND USES THEREOF TO TREAT TRAUMATIC BRAIN INJURY (TBI), INCLUDING CONCUSSIONS | BAKSHI, PANCHAM | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18702776 | BREATH-POWERED NASAL DEVICES FOR TREATMENT OF TRAUMATIC BRAIN INJURY (TBI), INCLUDING CONCUSSION, AND METHODS | HALL, DEANNA K | 215d overdue |
| 18653138 | C-20 STEROID COMPOUNDS, COMPOSITIONS AND USES THEREOF TO TREAT TRAUMATIC BRAIN INJURY (TBI), INCLUDING CONCUSSIONS | BAKSHI, PANCHAM | — |
| 14857331 | C-20 STEROID COMPOUNDS, COMPOSITIONS AND USES THEREOF TO TREAT TRAUMATIC BRAIN INJURY (TBI), INCLUDING CONCUSSIONS | BAKSHI, PANCHAM | — |
| Art Unit | Apps |
|---|---|
| 1623 | 2 |
| 3783 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18653138 | C-20 STEROID COMPOUNDS, COMPOSITIONS AND USES THEREOF TO TREAT TRAUMATIC BRAIN INJURY (TBI), INCLUDING CONCUSSIONS | BAKSHI, PANCHAM | 1623 | §101§102§103§112 | Non-Final OA | — | Pending | May 02, 2024 |
| 18702776 | BREATH-POWERED NASAL DEVICES FOR TREATMENT OF TRAUMATIC BRAIN INJURY (TBI), INCLUDING CONCUSSION, AND METHODS | HALL, DEANNA K | 3783 | §101§102§103 | Non-Final OA | 215d overdue | Pending | Apr 18, 2024 |
| 14857331 | C-20 STEROID COMPOUNDS, COMPOSITIONS AND USES THEREOF TO TREAT TRAUMATIC BRAIN INJURY (TBI), INCLUDING CONCUSSIONS | BAKSHI, PANCHAM | 1623 | §103 | Non-Final OA | — | Pending | Sep 17, 2015 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOragenics Inc. has 3 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Pancham Bakshi has the most, with 2 of Oragenics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
